We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Blood Test Identifies Key Alzheimer's Marker

By LabMedica International staff writers
Posted on 02 Aug 2017
Image: Histopathology of an immunostained diffuse amyloid beta plaque in a brain sample from a patient with Alzheimer’s disease (Photo courtesy of Dr. Dimitri P. Agamanolis, MD).
Image: Histopathology of an immunostained diffuse amyloid beta plaque in a brain sample from a patient with Alzheimer’s disease (Photo courtesy of Dr. Dimitri P. Agamanolis, MD).
Decades before people with Alzheimer's disease develop memory loss and confusion, their brains become dotted with plaques made of a sticky protein, called amyloid beta that is thought to contribute to the disease and its progression.

Currently, the only way to detect amyloid beta in the brain is via positron emission tomography (PET) scanning, which is expensive and not widely available, or a spinal tap, which is invasive and requires a specialized medical procedure.

Scientists at the Washington University School of Medicine (St. Louis, MO, USA) studied 41 people ages 60 and older. Twenty-three were amyloid-positive, meaning they had signs of cognitive impairment. PET scans or spinal taps in these patients also had detected the presence of amyloid plaques in the brain or amyloid alterations in the cerebrospinal fluid. They also measured amyloid subtypes in 18 people who had no buildup of amyloid in the brain.

The team measured blood levels of three amyloid subtypes: amyloid beta 38, amyloid beta 40, and amyloid beta 42 using highly precise measurement by mass spectrometry to see if any correlated with levels of amyloid in the brain. To measure amyloid levels, production and clearance over time, they drew 20 blood samples from each person over a 24-hour period.

Amyloid beta (Aβ) isoforms have a half-life of approximately three hours in plasma. Aβ38 demonstrated faster turnover kinetics compared with Aβ40 and Aβ42. Faster fractional turnover of Aβ42 relative to Aβ40 and lower Aβ42 and Aβ42/Aβ40 concentrations in amyloid-positive participants were observed. They found that levels of Aβ42 relative to Aβ40 were consistently 10% to 15% lower in the people with amyloid plaques. By averaging the ratio of Aβ42 to Aβ40 over each individual's 20 samples, the scientists could classify people accurately as amyloid-positive or amyloid -negative 89% of the time. On average, any single time point was also about 86% accurate.

Randall J. Bateman, MD, a Distinguished Professor of Neurology and the study's senior author said, “Our results demonstrate that this amyloid beta blood test can detect if amyloid has begun accumulating in the brain. This is exciting because it could be the basis for a rapid and inexpensive blood screening test to identify people at high risk of developing Alzheimer's disease.” The study was published on July 19, 2017, in journal Alzheimer's and Dementia.

Related Links:
Washington University School of Medicine


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240

Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more